Table 3 Adjusted odds ratio (AOR) and 95% confidence interval (CI) of clinical status and SERPINB5 rs2289520 genotypic frequencies in 302 HCC patients with tobacco consumption.

From: Serpin peptidase inhibitor (SERPINB5) haplotypes are associated with susceptibility to hepatocellular carcinoma

Variables

Genotypic frequencies

GG (N = 169)

GC + CC (N = 133)

OR (95% CI)

P value†

Clinical Stage

 Stage I/II

114 (67.5%)

84 (63.2%)

1.00

P = 0.435

 Stage III/IV

55 (32.5%)

49 (36.8%)

1.209 (0.750–1.948)

Tumor size

 ≦T2

118 (69.8%)

84 (63.2%)

1.00

P = 0.222

 >T2

51 (30.2%)

49 (36.8%)

1.350 (0.834–2.185)

Lymph node metastasis

 No

162 (95.9%)

131 (98.5%)

1.00

P = 0.181

 Yes

7 (4.1%)

2 (1.5%)

0.353 (0.072–1.730)

Distant metastasis

 No

156 (92.3%)

129 (97.0%)

1.00

P = 0.080

 Yes

13 (7.7%)

4 (3.0%)

0.372 (0.118–1.169)

Vascular invasion

 No

141 (83.4%)

115 (86.5%)

1.00

P = 0.466

 Yes

28 (16.6%)

18 (13.5%)

0.788 (0.415–1.497)

Child–Pugh grade†

 A

122 (72.2%)

109 (82.0%)

1.00

P = 0.047*

 B or C

47 (27.8%)

24 (18.0%)

0.527 (0.328–0.996)

HBsAg

 Negative

107 (63.3%)

70 (52.6%)

1.00

P = 0.061

 Positive

62 (36.7%)

63 (47.4%)

1.553 (0.978–2.466)

Anti–HCV

 Negative

79 (46.7%)

77 (57.9%)

1.00

P = 0.054

 Positive

90 (53.3%)

56 (42.1%)

0.638 (0.404–1.009)

Liver cirrhosis

 Negative

30 (17.8%)

35 (26.3%)

1.00

P = 0.072

 Positive

139 (82.2%)

98 (73.7%)

0.604 (0.348–1.049)

  1. The ORs with analyzed by their 95% CIs were estimated by logistic regression models. >T2 indicated the multiple tumor more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s). *P value < 0.05 as statistically significant.
  2. †Child-Pugh grades indicate the severity of cirrhosis: A = 5–6 points, B = 7–9 points and C = 10–15 points.
Back to article page